ANDA 91298, held by Torrent Pharmaceuticals. Pioglitazone Hydrochloride.
As of Nov 21, 2026, ANDA 91298 (Pioglitazone Hydrochloride), held by Torrent Pharmaceuticals, was first approved by FDA on Feb 13, 2013, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 13, 2013 | Original application | Approved | None posted |
| Pioglitazone HydrochlorideEQ 15MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Pioglitazone HydrochlorideEQ 30MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Pioglitazone HydrochlorideEQ 45MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Nov 27, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 27, 2018 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 27, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 13, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters